ESR1 and breast cancer: An analysis of 155,746 women with estrogen receptor-positive (ER+) early-stage breast cancer who were scheduled to receive five years of ET demonstrated a 10-year distant recurrence risk of 8%, 15%, and 30% for patients with zero, one to three, and four to nine positive nodes, respectively, during the years 2000–09 [4].